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was close to our predicted rate. We documented 34 primary outcome 
events and 117 total events incl IBR, 'all recurrences' (which included 
IBR, loco-regional and/or distant recurrence, and deaths). The 
numbers of events, percentages and confidence intervals were as 
follows, in each case for TARGIT vs EBRT.  IBR events 23 vs 11 ( 3.3% 
vs 1.3%, HR 2.07, CI 1.01 - 4.25 ); 'All recurrences' 69 vs 48 ( 8.2% vs 
5.7%, HR 1.44, CI 0.99-2.08 ); Deaths 37 vs 51 ( 3.9% vs 5.3%, HR 0.7, 
CI 0.46-1.07 ). Thus the IBR event rate was 2.0% higher with TARGIT-
IORT but was within our pre-set non-inferiority margin. In the pre-
pathology group ( approx two-thirds of all pts in study ) the IBR rate 
was 1.0%, and in post-pathology 3.7%. For the secondary outcome 
there was a non-significant trend towards improved overall survival 
for the TARGIT group ( HR 0.7, CI 0.46-1.07), due to fewer non-breast 
cancer deaths (17 vs 35 events, HR 0.47, CI 0.26-0.84). Cardiovascular 
deaths were 2 vs 11 and deaths from other cancers were 7 vs 16. 
Further analyses will be presented at the meeting. 
Conclusions: The risk-adapted approach using TARGIT-IORT resulted 
in a slightly higher IBR rate, though still at present within our pre-set 
'non-inferiority' margin. The pre-pathology group, i.e where the IORT 
was applied immediately after removal of the tumour, had a better 
outcome. The overall death rate was lower in the TARGIT group, due 
to a lower rate of non-breast cancer death.  
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Horizon 2020 is the financial instrument implementing the Innovation 
Union, a Europe2020 flagship initiative aimed at securing Europe's 
global competitiveness. Running from 2014 to 2020 with an €80 billion 
budget, the EU’s new programme for research and innovation is part 
of the drive to create new growth and jobs in Europe. 
Compared to the previous tools, Horizon 2020 provides a single set of 
rules, combining all research and innovation funding currently 
provided through the 7FP, the innovation related activities of the 
Competitiveness and Innovation Framework Programme (CIP) and the 
European Institute of Innovation and Technology (EIT). 
Simplification in Horizon 2020 (compared to actual 7FP) will target 
three overarching goals: to reduce the administrative costs of the 
participants; to accelerate all processes of proposal and grant 
management and to decrease the financial error rate. 
Mainthree priorities 
Horizon 2020 will focus resources on three distinct, yet mutually 
reinforcing, priorities: 
-  Excellent Science 
This will raise the level of excellence in Europe's science base and 
ensure a steady stream of world-class research to secure Europe's 
long-term competitiveness. It will support the best ideas, develop 
talent within Europe, provide researchers with access to priority 
research infrastructure, and make Europe an attractive location for 
the world's best researchers. 
This will: 
- support the most talented and creative individuals and their teams 
to carry out frontier research of the highest quality by building on the 
success of the European Research Council; 
- fund collaborative research to open up new and promising fields of 
research and innovation through support for Future and Emerging 
Technologies (FET); 
-  provide researchers with excellent training and career development 
opportunities through the Marie Sklodowska-Curie actions15 ('Marie 
Curie actions'); 
- ensure Europe has world-class research infrastructures (including e-
infrastructures) accessible to all researchers in Europe and beyond. 
-  Industrial Leadership 
This will: 
- build leadership in enabling and industrial technologies, with 
dedicated support for ICT, nanotechnologies, advanced materials, 
biotechnology, advanced manufacturing and processing, and space, 
while also providing support for cross-cutting actions to capture the 
accumulated benefits from combining several Key Enabling 
Technologies; 
- facilitate access to risk finance; 
- provide Union wide support for innovationin SMEs. 
- Societal Challenges 
This reflects the policy priorities of the Europe 2020 strategy and 
addresses major concerns shared by citizens in Europe and elsewhere. 
A challenge-based approach will bring together resources and 
knowledge across different fields, technologies and disciplines, 
including social sciences and the humanities. This will cover activities 
from research to market with a new focus on innovation-related 
activities, such as piloting, demonstration, test-beds, and support for 
public procurement and market uptake.It will include establishing 
links with the activities of the European Innovation Partnerships. 
Funding will be focused on the following challenges: 
- Health, demographic change and wellbeing; 
- Food security, sustainable agriculture, marine and maritime 
research and the bio-economy; 
- Secure, clean and efficient energy; 
- Smart, green and integrated transport; 
- Climate action, resource efficiency and raw materials; 
- Inclusive, innovative and secure societies. 
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Modern radiation oncology is a well-established,cost-effective and 
essential component in the curative and palliative treatment of 
malignancy. Indeed, these are exciting times for physicists and 
engineers in Radiotherapy. The challenge of individualized treatment 
optimization continuously drives research and technology, yet we 
should be careful not to get trapped in the “Cargo Cult Science” as 
described by Richard Feynman. In fact that same physicist once 
compared physics to sex by saying: “Sure, it may give some practical 
results, but that’s not why we do it.”  In an attempt of avoiding a 
blind gallop towards increasingly more precise means of tumour 
localization and delivery this physics perspective on research 
challenges will contemplate 3 topics: (a) Due to this cutting edge 
technology, one might argue that radiation oncology, long considered 
to be a physical intervention, is now more accurately conceptualized 
as a biologic intervention with profound effects at the cellular and 
molecular level. The big challenge is to bring these concepts into daily 
clinical routine. To quote yet another physicist, Paul Davis: “It’s like 
trying to run the economy of the US by measuring every transaction in 
every community and city.” (b) As systems become more automated 
and complex the potentials for failure become less intuitively obvious 
and we need more process-oriented rather than device oriented 
Quality Assurance to ensure patient safety. Quoting an ESTRO 
honorary physicist, Pierre Scalliet: “Complex technologies should 
therefore be managed with great foresight, particularly focusing on 
preventive management.” It suffices no longer to prove we can 
irradiate phantoms with high precision, patients demand proof of the 
true delivered dose in their particular case. (c) Scientific and 
technological progress comes at a significant cost,and many concerns 
exist regarding the value of that progress. Within these difficult 
economic times, healthcare politicians face the difficult challenge to 
create a furtive soil (e.g.supporting adequate reimbursement) 
allowing progress through efficacy and driven by outcomes. There is 
also a danger in that too much focus on sophisticated expensive 
technology may create a double layer health care system where not 
all patients have access to the best of care. Ideally, efforts in 
development should also aim at harmonizing the quality of care 
throughout Europe and the rest of the world. 
Technological developments in radiation oncology pave the way for 
tailored individualised therapy within the context of more 
sophisticated and complex treatments. However, the true 
individualised treatment using precise and biological conformal dose 
delivery, requires more than progress in one discipline only and the 
real progress awaits in the synergistic combination of the different 
disciplines allowing upfront identification of the most effective 
treatment for the individual patient and the possible adaptation based 
on response during treatment. This strategy can only work when the 
different treatment platforms evolve simultaneously and allow for 
optimal cross-fertilization. As always, with each step forward we 
realize there is an increased number of things we know too little 
about, or to quote Winston Churchill: “Every day you may make 
progress. Every step may be fruitful. Yet there will stretch out before 
you an ever-lengthening, ever-ascending, ever-improving path. You 
know you will never get to the end of the journey. But this, so far 
from discouraging, only adds to the joy and glory of the climb.”  
 
 
